TY - JOUR
T1 - Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
AU - Hujanen, Pekko
AU - Ruha, Heikki
AU - Lehtonen, Eemil
AU - Pirinen, Inka
AU - Huhtala, Heini
AU - Vaajanen, Anu
AU - Syvänen, Ulla
AU - Tuulonen, Anja
AU - Uusitalo-Järvinen, Hannele
N1 - Funding Information:
The study was supported by the Competitive Research Funding of the Pirkanmaa Hospital District for AV (grant nos. R18502 and 9X060), AT (grant no. 9AA076), PH and HU-J (grant nos. MJ006H, MK343 and MK270), Finnish Eye Foundation for PH, AV and HU-J, LUX—foundation for glaucoma research (AV), Eemil Aaltonen Foundation and Finnish Ophthalmologist Association for PH.
Publisher Copyright:
© 2023 Author(s). Published by BMJ.
PY - 2023
Y1 - 2023
N2 - Background/aims To analyse long-term outcomes of antivascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) using pro re nata (PRN) regimen in a single-centre clinical practice. Methods All patients receiving intravitreal injection (IVI) for nAMD between 1 January 2008 and 31 December 2020 were searched from electronic medical records. All 3844 treatment-naïve eyes of 3008 patients were included with a total of 50 146 IVIs (87% bevacizumab) administered. Main outcome measures were mean change in visual acuity (VA) from baseline, proportion of eyes within 15 letters of baseline, proportion of eyes with VA ≥20/40 Snellen and ≤20/200 Snellen, number of annual visits and number of annual IVIs. Results The mean baseline VA was 55 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and the mean change in VA from baseline was +2, +2, ±0, -2, -2 and -4 ETDRS letters at year 1, 2, 3, 5, 7 and 10, respectively. Proportions of eyes within 15 letters of baseline were 88%, 87%, 82%, 80%, 76% and 72% at the end of years 1, 2, 3, 5, 7 and 10, respectively. The median number of annual IVI was 6 at years 1-7 and 5 at year 10. The median number of annual total visits was 10 at year 1, 9 at years 2-7 and 8 at year 10, respectively. Conclusions VA was maintained short-term and long-term with anti-VEGF therapy using PRN treatment regimen.
AB - Background/aims To analyse long-term outcomes of antivascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) using pro re nata (PRN) regimen in a single-centre clinical practice. Methods All patients receiving intravitreal injection (IVI) for nAMD between 1 January 2008 and 31 December 2020 were searched from electronic medical records. All 3844 treatment-naïve eyes of 3008 patients were included with a total of 50 146 IVIs (87% bevacizumab) administered. Main outcome measures were mean change in visual acuity (VA) from baseline, proportion of eyes within 15 letters of baseline, proportion of eyes with VA ≥20/40 Snellen and ≤20/200 Snellen, number of annual visits and number of annual IVIs. Results The mean baseline VA was 55 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and the mean change in VA from baseline was +2, +2, ±0, -2, -2 and -4 ETDRS letters at year 1, 2, 3, 5, 7 and 10, respectively. Proportions of eyes within 15 letters of baseline were 88%, 87%, 82%, 80%, 76% and 72% at the end of years 1, 2, 3, 5, 7 and 10, respectively. The median number of annual IVI was 6 at years 1-7 and 5 at year 10. The median number of annual total visits was 10 at year 1, 9 at years 2-7 and 8 at year 10, respectively. Conclusions VA was maintained short-term and long-term with anti-VEGF therapy using PRN treatment regimen.
KW - Angiogenesis
KW - Macula
KW - Neovascularisation
KW - Retina
U2 - 10.1136/bmjophth-2023-001328
DO - 10.1136/bmjophth-2023-001328
M3 - Article
C2 - 37586826
AN - SCOPUS:85168249448
SN - 2397-3269
VL - 8
JO - BMJ Open Ophthalmology
JF - BMJ Open Ophthalmology
IS - 1
M1 - e001328
ER -
